From the *Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA; and †Division of Clinical Immunology and Rheumatology, School of Medicine, University of Alabama at Birmingham; and ‡Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham, AL; and §Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN.
J Clin Rheumatol. 2017 Oct;23(7):383-391. doi: 10.1097/RHU.0000000000000589.
Axial spondyloarthritis (AxSpA) is an inflammatory spondyloarthritis (SpA) that has significant impact on a patient's life. Symptoms, including fatigue, sleep problems, depression, and sexual dysfunction, can profoundly impact health-related quality of life (HRQoL) and limit work, leisure, and daily activities. Available therapies effectively manage pain and inflammation in early-stage disease, but patients often continue to experience impaired HRQoL. Thus, there remains a need for new therapies with novel mechanisms that can stop disease progression, potentially reverse damage caused by AxSpA and improve HRQoL in patients with AxSpA. Newer biologic agents, such as those targeting the interleukin 17-interleukin 23 axis, have promising efficacy and may improve HRQoL for patients with AxSpA. The AxSpA has many negative effects on HRQoL. By targeting disease pathways responsible for the development of AxSpA, approved and emerging therapies potentially reduce disease activity and improve the functional status of patients with AxSpA. This narrative review reflects on the findings of studies evaluating HRQoL of individuals with AxSpA and the role of newer therapies.
中轴型脊柱关节炎（AxSpA）是一种炎症性脊柱关节炎（SpA），对患者的生活有重大影响。疲劳、睡眠问题、抑郁和性功能障碍等症状会严重影响健康相关生活质量（HRQoL），并限制工作、休闲和日常活动。现有的治疗方法可以有效治疗早期疾病的疼痛和炎症，但患者往往仍会经历 HRQoL 受损。因此，仍需要具有新机制的新疗法，这些疗法可以阻止疾病进展，可能逆转 AxSpA 造成的损害，并改善 AxSpA 患者的 HRQoL。新型生物制剂，如靶向白细胞介素 17-白细胞介素 23 轴的制剂，具有良好的疗效，可能改善 AxSpA 患者的 HRQoL。AxSpA 对 HRQoL 有许多负面影响。通过针对导致 AxSpA 发展的疾病途径，已批准和新兴的治疗方法可能会降低疾病活动度并改善 AxSpA 患者的功能状态。本综述反映了评估 AxSpA 患者 HRQoL 的研究结果以及新型疗法的作用。
